Monofocal IOL Visual Outcomes When Targeting Mini Monovision

Inclusion Criteria: * Subject is undergoing bilateral cataract extraction with intraocular lens implantation. * Willing and able to provide written informed consent for participation in the study * Willing and able to comply with scheduled visits and other study procedures. * Scheduled to undergo standard cataract surgery in both eyes within 6 - 30 days between surgeries. * Subjects who require an IOL power in the range of +5.0 D to +34.0 D only. * Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes. Exclusion Criteria: * Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc. * Uncontrolled diabetes. * Use of any systemic or topical drug known to interfere with visual performance. * Contact lens use during the active treatment portion of the trial. * Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. * Clinically significant corneal dystrophy. * Irregular astigmatism. * History of chronic intraocular inflammation. * History of retinal detachment. * Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. * Previous intraocular surgery. * Previous refractive surgery. * Previous keratoplasty * Severe dry eye * Pupil abnormalities * Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e. LASIK) * Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc). * Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. * Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.